Leerink Partners analyst Puneet Souda maintained a Buy rating on Bio-Techne (TECH – Research Report) yesterday and set a price target of $80.00. The company’s shares closed yesterday at $48.10.

SIGNAL-AA Part B topline data readout on-track for 1H'26 -- WALTHAM, Mass., April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage ...

Bayer has launched the “Bayer Co.Lab Connect – Basel”, a new program specifically designed to empower early-stage startups as they navigate the U.S. ecosystem while building a strong partnership with ...

The company has developed a proprietary natural fiber liquid known as Fybron ™, that can be injected into 3D molds to create a variety of soft goods, which in many applications is fully bio-based and ...

Curi Bio, the industry leader in delivering human functional data to the drug discovery community, marked a significant milestone with the official ribbon-cutting ceremony at its new global ...

New state-of-the-art facility enhances capabilities to advance human-relevant drug discovery and development SEATTLE, April 08, 2025--(BUSINESS WIRE)--Curi Bio, the industry leader in delivering ...

The company has been recognized for... at 15:05 Curi Bio Celebrates Grand Opening of New Global Headquarters in Seattle Curi Bio, the industry leader in delivering human functional data to the ...

New state-of-the-art facility enhances capabilities to advance human-relevant drug discovery and development Curi Bio, the industry leader in delivering human functional data to the drug discovery ...

New state-of-the-art facility enhances capabilities to advance human-relevant drug discovery and development SEATTLE, April 08, 2025--(BUSINESS WIRE)--Curi Bio, the industry leader in delivering human ...

WARREN, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a healthcare company with dedicated efforts in immunotherapy and ...